Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwCLL 2023 | Currently available approaches for treating CLL

Francesco Forconi • 5 Oct 2023
iwCLL 2023
Chronic Lymphocytic Leukemia Leukemia BTK degraders BTK inhibitors Ibrutinib

Francesco Forconi, MD, DM, PhD, FRCPath, University of Southampton, Southampton, UK, outlines the treatment options available at present for patients with chronic lymphocytic leukemia (CLL) and discusses the current development of novel BTK degraders. This interview took place at the 20th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Boston, MA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved

More from Francesco Forconi

3:48
Using BTK degraders as a treatment strategy for patients with CLL
Francesco Forconi • 5 Oct 2023
2:31
Treatment considerations for IgHV-unmutated and mutated CLL
Francesco Forconi • 4 Apr 2022
2:01
Novel combination therapies for the treatment of CLL
Francesco Forconi • 4 Apr 2022
2:53
Highlights from the lymphoma and CLL session
Francesco Forconi • 4 Apr 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals